David Shaw’s Viking Therapeutics VKTX Stock Holding History

David Shaw’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-65,000	Closed	-$3.45M	–	4925
2024 Q2	$3.45M	Buy	+65,000	New	+$4.26M	﹤0.01%	2151

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

David Shaw's VKTX Position: Q2 2026 in Review

David Shaw reduced its Viking Therapeutics (VKTX) stake by 4.2% in Q2 2026, selling an estimated $2.28M and leaving 1,605,994 shares worth $62.6M. The position accounts for 0.03% of the portfolio, ranked #651.

David Shaw first reported a position in VKTX in Q2 2018 and has held it in 27 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

David Shaw held 1,605,994 shares of Viking Therapeutics worth $62.6M as of Q2 2026.
David Shaw sold 70,719 Viking Therapeutics shares in Q2 2026, an estimated $2.28M.
Viking Therapeutics made up 0.03% of David Shaw's portfolio in Q2 2026, its #651 holding.
David Shaw first reported a position in Viking Therapeutics in Q2 2018 and has held it in 27 quarters since.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.